• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, May 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Bacteria from cystic fibrosis patient could help thwart antibiotic-resistant TB

Bioengineer by Bioengineer
June 14, 2017
in Biology
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The number of drug-resistant tuberculosis (TB) cases is rising globally. But a newly discovered natural antibiotic — produced by bacteria from the lung infection in a cystic fibrosis patient — could help fight these infections. Lab testing reported in the Journal of the American Chemical Society shows that the compound is active against multi-drug resistant strains.

Starting with the famous first discovery of penicillin from mold, scientists have continued to search for natural sources of antibiotics. And as pathogens develop resistance to once-reliable medicines, the search has taken on a new urgency. By 2040, more than a third of all TB cases in Russia, for example, could show resistance to first-line drugs currently used to fight the disease, a recent report published in Lancet estimates. Among potential new drug sources are species of the bacterial genus Burkholderia that thrive in a wide range of habitats, from soil to the human lung. One way these microbes have adapted to these diverse environments is by making potent antibiotics to take out their competition. In light of the growing threat of drug-resistant bacteria, particularly among TB strains, Gregory L. Challis, Eshwar Mahenthiralingam and colleagues wanted to see if Burkholderia might produce a promising anti-TB compound.

The researchers discovered that one species, Burkholderia gladioli, which was isolated from the sputum of a child with cystic fibrosis, produces an antibiotic called gladiolin. The compound belongs to the same structural class as etnangien, another antibiotic that has been investigated for its ability to jam bacterial cell machinery. But etnangien is highly unstable. The researchers found that gladiolin is much more stable than etnangien, and could therefore potentially be a better drug candidate. Lab testing also showed that gladiolin blocked the growth of four drug-resistant TB strains.

###

The authors acknowledge funding from the Biotechnology and Biological Sciences Research Council (U.K.), the Wales Life Sciences Bridging Fund and a Marie Sklodowska-Curie Actions Fellowship.

The abstract that accompanies this study is available here.

The American Chemical Society, the world's largest scientific society, is a not-for-profit organization chartered by the U.S. Congress. ACS is a global leader in providing access to chemistry-related information and research through its multiple databases, peer-reviewed journals and scientific studies. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact [email protected].

Follow us on Twitter | Facebook

Media Contact

Katie Cottingham
[email protected]
301-775-8455
@ACSpressroom

http://www.acs.org

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Breakthrough Cancer Treatment Effective Across All Organ Types — Biology

Breakthrough Cancer Treatment Effective Across All Organ Types

May 18, 2026
Butyrate Alleviates Temporomandibular Joint Pain via Epigenetic Mechanisms — Biology

Butyrate Alleviates Temporomandibular Joint Pain via Epigenetic Mechanisms

May 18, 2026

How Hibernation Impacts Visual Processing in Squirrels’ Brains

May 18, 2026

PKU Researchers Pioneer First-in-Class Drug Candidate Targeting Cholestatic Itch

May 18, 2026
Please login to join discussion

POPULAR NEWS

  • Research Indicates Potential Connection Between Prenatal Medication Exposure and Elevated Autism Risk

    845 shares
    Share 338 Tweet 211
  • New Study Reveals Plants Can Detect the Sound of Rain

    731 shares
    Share 292 Tweet 182
  • Salmonella Haem Blocks Macrophages, Boosts Infection

    62 shares
    Share 25 Tweet 16
  • Breastmilk Balances E. coli and Beneficial Bacteria in Infant Gut Microbiomes

    58 shares
    Share 23 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Leveraging Technology to Enhance Emergency Response for Cardiac and Stroke Cases

Protein Engineering and Testing Condensed into One Day

Machine Learning Pinpoints Immunotherapy Targets, Validated by Tumor Explants

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.